News | Structural Heart | January 04, 2024

Laguna Tech USA Announces Site Record Number of Transcatheter Heart Valves Implanted at Single Center on Same Day in First-in-Human Clinical Trial

Five implants successfully accomplished at the Instituto Nacional de Torax in Santiago, Chile with advanced engineered heart valve, ZETA, designed to provide flexibility and optionality regardless of high, low or zero calcification

Five implants successfully accomplished at the Instituto Nacional de Torax in Santiago, Chile with advanced engineered heart valve, ZETA, designed to provide flexibility and optionality regardless of high, low or zero calcification

Getty Images


January 4, 2024 — Laguna Tech USA, a privately-held medical technology company dedicated to innovations in structural heart solutions to broaden useability and applicability for patients, today announced that a record number five patients were successfully treated at a single center on the same day with the ZETA Balloon Expandable Aortic Valve System to treat aortic valve disease. In all cases, patients achieved complete resolution of aortic disease with no residual stenosis or regurgitation immediately following the procedure, and all patients were discharged within 24-48 hours of the procedure. The high volume of procedures was made possible due to the versatility and flexibility of the novel design of the ZETA system, which provides greater ease of implantability for a broader patient population than currently approved valve systems. All five implants were accomplished on the same day at the Instituto Nacional de Torax in Santiago, Chile within the ongoing feasibility trial for the ZETA system.

The ZETA system is a novel balloon-expandable transcatheter valve with six expanding arms and a low profile covered delivery system.

Dr. Christian Dauvergne, Chief of Interventional Cardiology, Instituto Nacional de Torax, added, “Our ability to successfully implant the ZETA Aortic Valve in five patients with complex, diverse clinical profiles on a single day was due to the very simple and efficient design characterized by a low profile and straightforward transcatheter system, which allows for simple, advantageous placement in the heart. I look forward to the continued development of the ZETA device to explore the potential of this breakthrough technology to treat more patients with aortic regurgitation with unmet needs.”

The lead primary investigator, Dr. Scott Lim, a cardiologist from the University of Virginia noted, “The treatment of complex and diverse aortic valve disease patients at the center in Santiago was an impressive accomplishment, as was the highly reproducible landing of the ZETA valve relative to the aortic annulus, regardless of the degree or lack of calcium, which speaks to the potential of the balloon-expandable ZETA Aortic Valve. We treated patients both with severe, non-calcific aortic regurgitation as well as those with highly calcific aortic stenosis, and in all cases there was no paravalvar regurgitation. Additionally, by fluoroscopy, all implanted ZETA valves were consistently implanted within two millimeters of the annulus. I look forward to the upcoming pivotal clinical trials on the ZETA valve.”

“We are thrilled with this significant and rapid progress in the development of the ZETA valve,” said Gilbert Madrid, chief executive officer of Laguna Tech USA. “Together with the encouraging data we have generated with our other device, the ALPHA valve and its successful implants, we are making important advancements in realizing the promise of our next-generation, differentiated aortic valves. With two varying valve designs, each leveraging advanced technology and engineering of existing products on the market, we look forward to the potential of our technology to significantly expand the number of patients with aortic valve regurgitation who may be treated with our minimally invasive treatment options. We look forward to scaling this technology and moving into later stage clinical development so we can bring this technology to a greater population of patients.”

For more information: https://lagunatechventures.com/


Related Content

News | Structural Heart

April 9, 2024 — UC Davis Health cardiology team members are among the first in the country to treat patients with ...

Home April 09, 2024
Home
News | Structural Heart

March 25, 2024 — In a groundbreaking medical advancement, three esteemed cardiologists from CLS Health, Dr. Bahaeddin ...

Home March 25, 2024
Home
News | Structural Heart

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

Home March 12, 2024
Home
News | Structural Heart

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
News | Structural Heart

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

Home February 15, 2024
Home
News | Structural Heart

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

Home February 09, 2024
Home
News | Structural Heart

December 12, 2023 — Think of them as the Energizer Bunnies of the heart, tiny natural batteries that keep this vital ...

Home December 12, 2023
Home
News | Structural Heart

October 31, 2023 — Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized ...

Home October 31, 2023
Home
News | Structural Heart

October 26, 2023 — Abbott announced data from late-breaking presentations showing the impact of its minimally invasive ...

Home October 26, 2023
Home
News | Structural Heart

October 19, 2023 — The Dib UltraNav Transseptal Catheter System, which houses a needle and ultrasound in one system for ...

Home October 19, 2023
Home
Subscribe Now